Cargando…

Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges

Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Zuber, Gupta, Ghanshyam Das, Mehan, Sidharth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342392/
https://www.ncbi.nlm.nih.gov/pubmed/37445309
http://dx.doi.org/10.3390/jcm12134274
_version_ 1785072488150990848
author Khan, Zuber
Gupta, Ghanshyam Das
Mehan, Sidharth
author_facet Khan, Zuber
Gupta, Ghanshyam Das
Mehan, Sidharth
author_sort Khan, Zuber
collection PubMed
description Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in detecting and treating multiple sclerosis in India. A lack of MS knowledge among healthcare professionals and the general public, which delays diagnosis and treatment, is one of the significant issues. Inadequate numbers of neurologists and professionals with knowledge of MS management also exacerbate the situation. In addition, MS medications are expensive and not covered by insurance, making them inaccessible to most patients. Due to the absence of established treatment protocols and standards for MS care, India’s treatment techniques vary. In addition, India’s population diversity poses unique challenges regarding genetic variations, cellular and molecular abnormalities, and the potential for differing treatment responses. MS is more difficult to accurately diagnose and monitor due to a lack of specialized medical supplies and diagnostic instruments. Improved awareness and education among healthcare professionals and the general public, as well as the development of standardized treatment regimens and increased investment in MS research and infrastructure, are required to address these issues. By addressing these issues, it is anticipated that MS diagnosis and treatment in India will improve, leading to better outcomes for those affected by this chronic condition.
format Online
Article
Text
id pubmed-10342392
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103423922023-07-14 Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges Khan, Zuber Gupta, Ghanshyam Das Mehan, Sidharth J Clin Med Review Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in detecting and treating multiple sclerosis in India. A lack of MS knowledge among healthcare professionals and the general public, which delays diagnosis and treatment, is one of the significant issues. Inadequate numbers of neurologists and professionals with knowledge of MS management also exacerbate the situation. In addition, MS medications are expensive and not covered by insurance, making them inaccessible to most patients. Due to the absence of established treatment protocols and standards for MS care, India’s treatment techniques vary. In addition, India’s population diversity poses unique challenges regarding genetic variations, cellular and molecular abnormalities, and the potential for differing treatment responses. MS is more difficult to accurately diagnose and monitor due to a lack of specialized medical supplies and diagnostic instruments. Improved awareness and education among healthcare professionals and the general public, as well as the development of standardized treatment regimens and increased investment in MS research and infrastructure, are required to address these issues. By addressing these issues, it is anticipated that MS diagnosis and treatment in India will improve, leading to better outcomes for those affected by this chronic condition. MDPI 2023-06-26 /pmc/articles/PMC10342392/ /pubmed/37445309 http://dx.doi.org/10.3390/jcm12134274 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Khan, Zuber
Gupta, Ghanshyam Das
Mehan, Sidharth
Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
title Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
title_full Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
title_fullStr Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
title_full_unstemmed Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
title_short Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
title_sort cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342392/
https://www.ncbi.nlm.nih.gov/pubmed/37445309
http://dx.doi.org/10.3390/jcm12134274
work_keys_str_mv AT khanzuber cellularandmolecularevidenceofmultiplesclerosisdiagnosisandtreatmentchallenges
AT guptaghanshyamdas cellularandmolecularevidenceofmultiplesclerosisdiagnosisandtreatmentchallenges
AT mehansidharth cellularandmolecularevidenceofmultiplesclerosisdiagnosisandtreatmentchallenges